Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma

By S. Wemmert, Yasmin Lindner, J. Linxweiler, Stefan Wagenpfeil, R. Bohle, M. Niewald, B. Schick. 2016

Subfields: Cancer Research, Oncology, Otorhinolaryngology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Knebel
2. Maximilian Linxweiler
3. S. Körner
4. L. Brust
5. Matthias Schneider
6. F. Braun
7. S. Wemmert
8. J. Kühn

Citations in the corpus

• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “So far, SEC62 expression and its correlation with clinical parameters including therapy outcome were only investigated in HNSCC cohorts that were predominately treated with surgery [22] or in very small cohorts treated with CRT [34].”